Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes

2015 ◽  
Vol 22 (8) ◽  
pp. 1145-1150 ◽  
Author(s):  
P. Zis ◽  
P. Martinez-Martin ◽  
A. Sauerbier ◽  
A. Rizos ◽  
J. C. Sharma ◽  
...  
2015 ◽  
Vol 86 (11) ◽  
pp. e4.80-e4
Author(s):  
Fahd Baig ◽  
Michael Lawton ◽  
Michal Rolinski ◽  
Claudio Ruffmann ◽  
Kannan Nithi ◽  
...  

ObjectiveTo delineate treatment and quality of life of non-motor symptoms (NMS) in early Parkinson's disease (PD) and first-degree relatives.BackgroundNon-motor symptoms (NMS) are an important prodromal feature of Parkinson's disease (PD). However, their frequency, treatment rates and impact on health-related quality of life (HRQoL) in the early motor phase is unclear.Methods769 population-ascertained PD subjects within 3.5 years of diagnosis and 287 control subjects were assessed. Validated severity questionnaires were employed to assess NMS symptoms across the following domains: (1) neuropsychiatric (2) gastrointestinal (3) sleep (4) sensory (5) autonomic (6) sexual. Health related quality of life (HRQoL), functional status and management were also evaluated.ResultsNMS were common in early PD. More than half of the PD cases had hyposmia, pain, fatigue, sleep disturbance or urinary dysfunction. PD cases had worse HRQoL scores than controls (OR 4.1, p<0.001) with depression, anxiety and pain being stronger drivers than MDS-UPDRS motor scores. Quality of life is affected in early PD, although 23% of participants reported no problems. NMS were rarely treated in routine clinical practice.ConclusionsDespite their major impact on HRQoL, NMS are usually under-recognised and treated. The use of screening tools could improve recognition and treatment of NMS in early PD.


2018 ◽  
Vol 26 (3) ◽  
pp. 400-406 ◽  
Author(s):  
X. Huang ◽  
S. Y.‐E. Ng ◽  
N. S.‐Y. Chia ◽  
F. Setiawan ◽  
K.‐Y. Tay ◽  
...  

US Neurology ◽  
2009 ◽  
Vol 05 (01) ◽  
pp. 25
Author(s):  
Binit Shah ◽  
Tanya Simuni ◽  
◽  

Parkinson’s disease (PD) is the second most common neurodegenerative disease and affects more than one million people in the US. The management of PD involves treatment of motor and non-motor symptoms of the disease. The armamentarium of treatment options for PD has increased substantially over the last 10 years. This article reviews recent clinical trials investigating efficacy, complications of treatment, and possible neuroprotective agents in patients with early PD.


2012 ◽  
Vol 84 (1) ◽  
pp. 14-17 ◽  
Author(s):  
Roberto Erro ◽  
Marina Picillo ◽  
Carmine Vitale ◽  
Marianna Amboni ◽  
Marcello Moccia ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document